Rate Control Drugs Research Articles

Frailty and anticoagulant prescription in older hospitalized patients with atrial fibrillation: a multi-centred observational study

Abstract Background Evidence of the impact of frailty on anticoagulant prescription in older people with atrial fibrillation (AF) is conflicting. Some studies suggested that oral anticoagulants (OACs) were underutilized in older people with frailty while others have not found this. Aims The primary aim of this study was to examine the prevalence of frailty in hospitalized older patients with AF and the association between frailty and OAC prescription during admission. The secondary aim was to examine the association between frailty and prescription of rate/rhythm control medications during admission. Methods This is a retrospective observational cohort study. Adults aged ≥65 years with AF admitted to six hospitals in Australia between 1 June 2022 and 31 August 2022 were eligible for this study. Frailty was defined by a Frailty Index constructed using information from the electronic medical records. Logistic regression models were applied to examine the association between frailty and the prescriptions of OACs, rate control drugs and rhythm control drugs during admission. Results are presented as odds ratios and 95% confidence intervals. Results A total of 685 patients were included in this analysis. They had a mean age of 82.6, and 49.8% were female. Using the cut-off point of 0.25, 42.8% of the patients were identified as being frail. Overall, 75.6% of the patients were prescribed OACs (67.9% in the frail compared to 81.4% in the non-frail, p<0.001), 37.7% received rate control drugs (42.0% in the frail versus 34.4% in the non-frail, p=0.044), while 27.3% received rhythm control drugs (22.9% in the frail compared to 30.6% in the non-frail, p=0.024). The adjusted odds ratios of frailty on prescriptions during admission were 0.53 (95%CI 0.37 – 0.78) for OACs, 1.45 (95%CI 1.05 – 1.99) for rate control drugs, and 0.79 (95%CI 0.55 – 1.13) for rhythm control drugs. Conclusion Our study found a high prevalence of frailty in older inpatients with AF and frailty was associated with a reduced likelihood of receiving OACs. Further studies are needed to understand the reasons for under-coagulation in frail patients with AF.Prescriptions of OACs during admission

Effect of catheter ablation vs medical therapy on cardiovascular outcomes in hypertrophic cardiomyopathy with atrial fibrillation

Abstract Background Atrial fibrillation (AF) increases the risks of stroke and mortality. AF ablation in patients with heart failure (HF) was associated with a lower risk of death and hospitalisation for worsening HF. Whether AF ablation is beneficial to improve cardiovascular outcomes in patients with concomitant hypertrophic cardiomyopathy (HCM) and AF remains unclear. Objective To investigate whether AF ablation is more effective than conventional medical therapy for improving outcomes in HCM. Methods 2,281 patients with HCM and AF undergoing catheter ablation or medical therapy (antiarrhythmic drugs or rate control drugs) in 2005–2015 were identified from the Korean National Health Insurance Service database. The primary composite outcome of death from cardiovascular causes, ischaemic stroke, hospitalization for worsening HF, or acute myocardial infarction was compared between catheter ablation and medical therapy using propensity score overlap weighting. The time-at-risk was counted from the first medical therapy, and catheter ablation was analysed as a time-varying exposure. Results Of the included (41.1% female; median age: 66 years), 145 (6.1%) underwent catheter ablation for AF during the study period. During a mean follow-up of 3.1 (IQR 1.3–5.8) years, a total of 831 composite outcomes occurred including 292 cardiovascular deaths and 401 strokes. Catheter ablation, compared with medical therapy, was associated with lower risks of the primary composite outcome (weighted incidence rate: 3.84 vs. 6.43 per 100 person-years; weighted HR 0.61, 95% CI 0.38–0.96) and ischaemic stroke (weighted HR 0.43, 95% CI 0.19–0.97). The association between ablation and a lower risk of composite outcome was more pronounced in cases of ablation success whereas no significant difference was observed in cases of ablation failure. Conclusions In patients with AF and HCM, catheter ablation was associated with a lower risk of adverse cardiovascular outcomes than medical therapy.

Effect of heart rate control with ivabradine on hemodynamic in patients with sepsis: study protocol for a prospective, multicenter, randomized controlled trial

IntroductionSepsis, a life-threatening syndrome, is often accompanied by tachycardia in spite of hypovolemia and hypotension have been corrected. Recently, relevant studies have shown that sustained tachycardia in sepsis was related to high mortality, and appropriate control of heart rate (HR) could improve prognosis. Ivabradine reduces HR directly without a negative inotropic effect through inhibition of the If ionic current, which is different from the traditional rate control drug (beta-blockers).Methods and analysisThis is a prospective, multicenter, randomized, open label study designed to investigate the effect of heart rate control with ivabradine on hemodynamic in patients with sepsis. Our study will enroll 172 patients with sepsis as defined by The Third International Consensus Definitions for Sepsis and Septic Shock criteria with sinus rate of 95 bpm or higher despite a hemodynamic optimization. Patients will be randomly assigned to standard treatment group (GS) or ivabradine group (GI, standard treatment for sepsis plus enteral ivabradine). Patients in GI will receive ivabradine to maintain HR between 70 and 94 bpm. The primary outcome is the difference of a reduction in HR below 95 bpm and the effect of ivabradine on hemodynamics between GI and GS group within the first 96 h after randomization. The secondary outcomes include organ function measures, the difference in SOFA score, incidence of adverse events, need for organ support, length of ICU stay, and 28-day overall mortality.DiscussionThere are limited studies on ivabradine to control heart rate in patients with sepsis. Our study aims to evaluate whether direct sinus node inhibition can improve hemodynamics, as well as its impact on organ function and prognosis in patients with sepsis, so as to provide evidence for the safe usage in clinical practice.Trial registrationClinicalTrials.gov NCT05882708. Registered on May 11, 2023, https://clinicaltrials.gov/ct2/show/NCT05882708.

Evaluation of the Results of Left Bundle Branch Pacing after Atrioventricular Junction Ablation in Patients with Chronic Atrial Fibrillation

Atrioventricular junction ablation (AVJA) together with the implantation of cardiac pacemaker has become a recognized and effective treatment strategy for patients with symptomatic tachysystolic atrial fibrillation that does not respond to heart rate control drug therapy. Left bundle branch pacing (LBBP) is a physiological alternative to right ventricular and biventricular pacing. The aim. To analyze the clinical results of the average duration with the use of LBBP and AVJA. Materials and methods. Over the period from January 2023 to July 2024, LBBP with subsequent AVJA was applied at the National Amosov Institute of Cardiovascular Surgery in 18 patients as a method of treatment of chronic tachysystolic atrial fibrillation to achieve heart rate control. Results. Mid-term results (at least 1 month) could be monitored in 15 out of 18 patients (84%); in the other three (16%) patients the time between pacemaker implantation and AVJA was too short. The mean period from pacemaker implantation to control examination was 5.07 ± 2.79 months (minimum period 1 month, maximum 12 months). During the period from implantation and ablation to the control observation in the study group, it was possible to observe an increase in left ventricular ejection fraction from 39.12 ± 10.56% to 46.38 ± 7.09%, p = 0.035; decrease in the values of end-diastolic volume from 184.22 ± 76.76 to 167.85 ± 36.93 ml, p = 0.074; decrease in the right ventricular pressure from 43.07 ± 8.29 to 34.38 ± 4.78 mm Hg, p = 0.013. It was also possible to observe a decrease in the left bundle branch capture thresholds from 1.27 ± 0.58 to 0.7 ± 0.39 V at 0.4 ms, p = 0.016; and a decrease in the average LBBP endocardial lead resistance from 638 ± 172.83 to 529.4 ± 120.15 Ohm, p = 0.012. Conclusions. Implantation of the LBBP pacemaker and AVJA was not associated with the occurrence of complications both in the intraoperative and postoperative periods, as well as in the remote period of the average duration in the studied group. The use of this approach in patients with chronic atrial fibrillation made it possible in a series of consecutive patients to improve the systolic function of the left ventricle, to reduce the values of the end-diastolic volume of the left ventricle and the right ventricular pressure at optimal pacing parameters.

Characterizing atrial fibrillation in patients with and without heart failure across the ejection fraction spectrum: Incidence, prevalence, and treatment strategies.

Heart failure (HF) and atrial fibrillation (AF) often coexist. We explored AF incidence, prevalence, and treatment strategies in patients with versus without HF across the ejection fraction (EF) spectrum. We analysed patients with HF from the Swedish HF Registry (1 December 2005-31 December 2021), matched 1:1 by sex, age, and county of residence to patients without HF from Statistics Sweden. Two study cohorts were derived (i) to assess AF prevalence and treatments, and (ii) to evaluate AF incidence and related predictors. Overall, 195 106 patients were considered, 50% of them with HF (of whom 54% with HF with reduced [HFrEF], 23% mildly reduced [HFmrEF], and 23% with preserved EF [HFpEF]). From 2006 to 2021, AF prevalence increased in both patients with (57% to 58%) and without HF (8% to 11%). HF patients, particularly if with HFrEF, were more likely receiving AF treatments than those without HF. Over time, antiarrhythmic use decreased, while rate control drugs and oral anticoagulant use, and AF-related procedures increased, regardless of HF and EF. During a median follow-up of 3.7 years, in 86 210 patients without AF, incident AF risk was two-fold higher in HF versus non-HF (hazard ratio [HR] 2.76, 95% confidence interval [CI] 2.45-3.12), highest in HFpEF (HR 3.12, 95% CI 2.65-3.67) versus HFrEF (HR 2.68, 95% CI 2.34-3.06) and HFmrEF (HR 2.53, 95% CI 2.17-2.94). Atrial fibrillation prevalence, anticoagulant use, and AF-related procedures increased over time regardless of HF, with HF patients more likely receiving AF treatments. In HF, despite higher AF prevalence and incidence in HFpEF, AF treatment use remained modest, calling for further implementation.

Risk Factors for Treatment Transition in Patients with Low-Risk Atrial Fibrillation Patients Undergoing Anticoagulation Monotherapy: A Large Claims Database Study in Japan.

The global prevalence of atrial fibrillation (AF) is rising, paralleling increased life expectancy. Early rhythm control benefits AF management. However, in low-risk, often asymptomatic, AF patients, anticoagulant monotherapy is the selected treatment, aligning with current guidelines. However, early AF progression in these low-risk individuals is not well-understood. Thus, this study aims to: 1) determine the proportion of low-risk AF patients who worsen within a year of initial AF diagnosis and 2) identify risk factors such treatment transitions. We analyzed data from 18623 AF patients, spanning January 2005 to June 2017. Low-risk patients were those on anticoagulant monotherapy ± rate control, following the JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. We defined 2 patterns of treatment transition for 1) initiating ablation or antiarrhythmic drug therapy and 2) solely using antiarrhythmic drugs. This retrospective cohort study was employed a 12-month study, following a 6-month screening period. We included 1874 patients for all rhythm control (analysis 1) and 1503 for only medication-based control (analysis 2). The primary endpoint, treatment transition of AF under monotherapy, occurred in 28.4% of patients in analysis 1 and 10.8% in analysis 2. Risk factors common to both scenarios were male gender, baseline rate control drug use, and rivaroxaban selection, as identified by multiple logistic regression. These findings suggest a higher AF treatment transition trend in patients starting rivaroxaban, calling for further research. The study highlights the importance of informed early rhythm control initiation decisions in clinical settings.

Model-based estimation of AV-nodal refractory period and conduction delay trends from ECG.

Introduction: Atrial fibrillation (AF) is the most common arrhythmia, associated with significant burdens to patients and the healthcare system. The atrioventricular (AV) node plays a vital role in regulating heart rate during AF by filtering electrical impulses from the atria. However, it is often insufficient in regards to maintaining a healthy heart rate, thus the AV node properties are modified using rate-control drugs. Moreover, treatment selection during permanent AF is currently done empirically. Quantifying individual differences in diurnal and short-term variability of AV-nodal function could aid in personalized treatment selection. Methods: This study presents a novel methodology for estimating the refractory period (RP) and conduction delay (CD) trends, and their uncertainty in the two pathways of the AV node during 24 h using non-invasive data. This was achieved by utilizing a network model together with a problem-specific genetic algorithm and an approximate Bayesian computation algorithm. Diurnal variability in the estimated RP and CD was quantified by the difference between the daytime and nighttime estimates, and short-term variability was quantified by the Kolmogorov-Smirnov distance between adjacent 10-min segments in the 24-h trends. Additionally, the predictive value of the derived parameter trends regarding drug outcome was investigated using several machine learning tools. Results: Holter electrocardiograms from 51 patients with permanent AF during baseline were analyzed, and the predictive power of variations in RP and CD on the resulting heart rate reduction after treatment with four rate control drugs was investigated. Diurnal variability yielded no correlation to treatment outcome, and no prediction of drug outcome was possible using the machine learning tools. However, a correlation between the short-term variability for the RP and CD in the fast pathway and resulting heart rate reduction during treatment with metoprolol (ρ = 0.48, p < 0.005 in RP, ρ = 0.35, p < 0.05 in CD) were found. Discussion: The proposed methodology enables non-invasive estimation of the AV node properties during 24 h, which-indicated by the correlation between the short-term variability and heart rate reduction-may have the potential to assist in treatment selection.

Standardized community management on the diagnosis, treatment, and risk factors control for non-valvular atrial fibrillation in elderly patients

BackgroundBy investigating the knowledge, medication, occurrence of complications, and risks among elderly non-valvular atrial fibrillation (NVAF) patients in Shanghai communities, and providing standardized comprehensive management and follow-up, we aim to explore the impact of standardized community management on improving disease awareness, standardizing atrial fibrillation (AF) treatment, reducing the risk of complications occurrence, and addressing risk factors for AF patients.MethodsThis research selected elderly atrial fibrillation patients from Zhuanqiao Community Health Service Center, Minhang District, Shanghai from July 2020 to October 2022. Their personal health records and examination results were reviewed, and the incidence of AF, awareness, medication, and complications were investigated. Age-adjusted Charlson Comorbidity Index (aCCI), CHA2DS2-VASc score, and HAS-BLED score were used to evaluate disease burden, thromboembolic risk, and bleeding risk, respectively. The patients were subjected to standardized community management, and the compliance rate of disease awareness, treatment, resting heart rate, blood pressure, fasting blood glucose, and body mass index (BMI) were assessed at the baseline, 6 months and 1 year after management.ResultsA total of 243 NVAF patients were included, with an average aCCI score of (4.5 ± 1.1). Among them, 28% of the patients were aware of their AF, and 18.1% of the patients were aware of the hazards of AF. Of the patients, 11.9% used anticoagulant drugs, including 6.6% and 5.3% for warfarin and non-vitamin K antagonist oral anticoagulants (NOACs), respectively. 7% of patients used antiplatelet drugs. 26.7% of the patients used heart rate control drugs. 10.3% of the patients experienced thromboembolic events, and 0.8% of the patients experienced bleeding events. 93.0% of the patients were at high risk of thromboembolism, and 24.7% of the patients were at high risk of bleeding. Compared with the baseline, there were significant statistical differences (P < 0.001) in disease awareness, awareness of the hazards of AF, use of anticoagulant drugs and heart rate control drugs, and control of risk factors among NVAF patients after standardized community management. Moreover, with the extension of management time, there was a linear increase in the awareness of NVAF, awareness of the hazards of AF, utilization rate of anticoagulant drugs, utilization rate of heart rate control drugs, blood pressure, blood glucose, and BMI compliance rate (P < 0.001).ConclusionCurrently, the awareness, treatment, and control of risk factors for AF in elderly NVAF patients in Shanghai community are not satisfactory. Standardized community management helps to improve the diagnosis, treatment, and control of risk factors in AF.

Knowledge and unmet needs of patients with atrial fibrillation in China: a nationwide cross-sectional survey

Abstract Background Knowledge about the disease and treatment options is necessary for active patient engagement in shared decision-making, which is essential for ’patient-centered’ atrial fibrillation (AF) management. Purpose To evaluate the knowledge level and identify unmet needs of patients with AF in China. Methods A nationwide cross-sectional survey was conducted using online or paper questionnaires between May and August 2022. Adult AF outpatients or inpatients in China were eligible for participation. The questionnaires included items on knowledge regarding AF, treatment options, risk factors, AF treatment practice, and AF patients’ unmet needs. Results This survey included 2,002 patients with AF [mean age 68.62±13.45, 1,040 (52%) men] from 55 centers across 17 provinces in China. Most patients (66.18%) had knowledge scores of &amp;lt; 4 (an 8-item disease knowledge scale, the score ranged from 0 [worst] to 8 [best]), which is a poor knowledge level. Approximately half of the patients did not know that "AF can cause blood clots which can lead to stroke (cerebral infarction)." The proportion of patients who knew about oral anticoagulants, cardiac rhythm/heart rate control drugs, and catheter ablation were 85.96%, 81.37%, and 41.36%, respectively. However, only 79.52%, 72.08%, and 16.18% of patients received these respective treatments. Moreover, only 51.46% of patients were satisfied or very satisfied with their treatments. The improvement in life quality, prevention and treatment of complications, and symptom control were the three most important aspects for patients when choosing treatments. The impact of AF on daily activities, sleep, emotions, and memory were reported by 80.77%, 63.54%, 52.80%, and 66.18% patients, respectively. Most patients with AF recognized hypertension (87.50%) and diabetes mellitus (50.33%) as risk factors, but few recognized obesity and excessive alcohol intake. Overall, 93.56% of patients obtained AF knowledge from physicians. They expect the source of knowledge to include regular community education(61.29%), as well as digital tools(58.74%) between physicians and patients. Furthermore, 90.86% of patients considered involvement in treatment decisions necessary. Conclusions This study reveals that the knowledge level of patients with AF in China regarding the disease and treatment options is insufficient, and there remain unmet needs for AF management. Thus, more patient-centered education through multiple channels is required to improve patients' involvement in treatment decisions.

Antiarrhythmic Potential of Epicardial Botulinum Toxin Injection for Suppression of Postoperative Atrial Fibrillation.

Following heart surgery, postoperative atrial fibrillation (AF) is the most prevalent kind of secondary AF and the most frequent adverse event. Postoperative AF is related to a number of unfavorable cardiac outcomes, such as heart failure, stroke, and death. However, the pharmacological treatment for postoperative AF is only relatively efficient and is frequently linked to detrimental complications, including symptomatic bradycardia with atrioventricular block due to rate control drugs and elevated hemorrhage hazard attributable to the administration of anticoagulants. Ablation procedures also result in the irreversible damage of cardiac anatomic structures, which may have long-term negative implications on heart performance. As a result, there is an unmet demand for treatments that can minimize the incidence of postoperative AF in an effective and safe manner. Botulinum toxin is an established neurotoxin that has progressively gained use in every medical science domain. It hinders the propagation of impulses across nerve fibers without causing immediate damage to the cardiac tissue. The transient feature of botulinum toxin action and the eventual restoration of the autonomic nervous system transmission are undeniably advantageous and may render botulinum toxin a potential and feasible treatment approach for postoperative AF.

Rate control in atrial fibrillation, calcium channel blockers versus beta-blockers

ObjectiveTo investigate heart rate differences between non-dihydropyridine calcium channel blockers and beta-blockers in patients with non-permanent atrial fibrillation (AF).MethodsUsing data from ‘A Comparison of Rate Control and Rhythm Control in...

Rate control with calcium channel blockers versus betablockers in patients with paroxysmal and persistent atrial fibrillation - data from the AFFIRM trial

Abstract Funding Acknowledgements Type of funding sources: None. Purpose To investigate whether there are differences between nondihydropyridine calcium channel blockers and beta blockers on heart rate in patients with paroxysmal and persistent atrial fibrillation (AF). Methods In present analysis of the AFFIRM trial, the effect of rate control drugs on heart rate was evaluated during first reported AF-episode as well as the last recorded sinus rhythm episode prior to AF. Patients who used both rate control drugs or switched rate control drugs between the last sinus rhythm and the first AF episode were excluded. Results A total of 1195 patients were in sinus rhythm at baseline and used either betablockers (603, 50%) or non-dihydropyridine channel blockers (592, 50%). Of the total, 513 had at least one episode of AF while remaining on the same rate control drug, 257 (50%) of them using calcium channel blockers and 256 (50%) of them using betablockers. Mean age of patients treated with a calcium channel blocker was 70±8 years versus 68±8 for the betablocker treated patients (p=0.014). Forty-four percent were women, 31% with paroxysmal AF, and 69% with persistent AF. A resting heart rate &amp;lt;110 bpm during AF (lenient rate control) was achieved in 92% of patients using beta blockers and 93% of patients using calcium channel blockers (P= 0.724). Bradycardia during sinus rhythm (&amp;lt;60 bpm) occurred significantly less often in patients using calcium channel blockers (19%) versus betablockers (32% , P = 0.001). After adjusting for differences in patient characteristics, the association between calcium channel blockers and a reduction in sinus bradycardia remained statistically significant (OR = 0.40, 95% CI = 0.10-0.68). Conclusion In patients with persistent or paroxysmal AF included in the AFFIRM trial, nondihydropyridine calcium channel blocker as rate control treatment was associated with less bradycardia during sinus rhythm compared to betablockers. Resting heart rates &amp;lt;110 bpm during AF were achieved similarly in those treated with calcium channel blockers and betablockers.

CE-452779-1 IVABRADINE FOR CONTROLLING HEART RATE IN PERMANENT ATRIAL FIBRILLATION: RESULTS OF THE TRANSLATIONAL CLINICAL TRIAL BRAKE-AF

Ivabradine has been postulated to reduce the ventricular rate in atrial fibrillation. However, the mechanisms responsible for that reduction and its performance as rate-control drug are not known To evaluate the mechanism of inhibition of atrioventricular conduction produced by ivabradine and to determine its efficacy and safety compared with digoxin in permanent atrial fibrillation The effects of ivabradine in atrioventricular nodal and ventricular cells were studied by in-vitro whole-cell patch-clamp experiments . Changes in If, INa, ICaL, ICaT, IKs, IKr, and IK1 conductances were integrated in mathematical simulations of nodal and ventricular action potentials. In parallel, a multicenter, randomized, open-label, phase III clinical trial compared ivabradine (5mg BID increased to 7.5mg BID after one month) versus digoxin (0.10-0.25mg QD adjusted by serum levels) for uncontrolled permanent atrial fibrillation despite beta-blockers or calcium channel blockers. Primary efficacy and safety endpoints were the reduction of the mean daytime heart rate at 3 months and a combination of syncope, clinically significant bradycardia or serious drug-related adverse events, respectively. The primary efficacy endpoint was evaluated by intention to treat using the O'Brien–Fleming method. Safety endpoints were evaluated with χ2 or Fisher’s exact tests Ivabradine 1 μM inhibited If and IKr by 28.9% and 22.8% (P<0.05) respectively. INa and ICaL were also reduced but only at 10 μM. Ivabradine slowed the firing frequency of a modelled human AV nodal action potential by 10.6% and induced a minimal prolongation of the ventricular action potential. The clinical trial randomized 35 patients to ivabradine and 33 to digoxin. Mean daytime heart rate decreased by 11.6 bpm (-11.5%) in the ivabradine arm (p=0.02) Vs 19.6 (-20.6%) in the digoxin arm (p<0.001) however, the non-inferiority margin of efficacy was not met (Z:-1.95; p=0.97). Primary safety endpoint occurred in 3 (8.6%) patients on ivabradine and in 8 (24.2%) on digoxin (p=0.10). Therapeutic adherence was lower in the digoxin arm (78.8% vs. 97.1%; p=0.02) Ivabradine produced a discrete heart rate reduction in patients with permanent atrial fibrillation. Compared with digoxin, ivabradine was less effective, better tolerated and had a similar rate of serious adverse events.The inhibition of If in the AV node seems the main mechanism responsible for the ivabradine-induced heart rate reduction in atrial fibrillation.

Ventricular rate in atrial fibrillation and the risk of heart failure and death.

While clinical trials have suggested that a high ventricular rate is associated with increased risk of heart failure (HF) and mortality, all-comers studies are warranted. To assess 1-year risk of new-onset diagnosed HF and all-cause mortality among rate-control treated patients presenting with atrial fibrillation (AF) on an electrocardiogram (ECG) according to ventricular rate. ECGs recorded at the Copenhagen General Practitioners Laboratory (2001-15) were used to identify patients with AF. Multivariate Cox proportional hazard regression models were used to compare risk of new-onset HF and all-cause mortality after first ECG presenting with AF according to ventricular rate on ECG [<60, 60-79, 80-99, and 100-110, > 110 beats per minute (bpm)]. We identified 7408 patients in treatment with rate control drugs at time of first ECG presenting with AF [median age 78 years (Q1,Q3 = 70-85 years)], 45.8% male, median ventricular rate 83 bpm, (Q1,Q3 = 71-101 bpm)]. During 1-year follow-up, 666 (9.0%) of all patients with AF developed HF and 858 (11.6%) died. Patients with AF ventricular rates 100-110 bpm and >110 bpm had a hazard ratio (HR) of 1.46 (CI: 1.10-1.95) and 2.41 (CI: 1.94-3.00) respectively for new-onset HF, compared with 60-79 bpm. Similarly, patients with AF ventricular rates 100-110 bpm and >110 bpm had a HR of 1.44 (CI: 1.13-1.82) and 1.34 (CI: 1.08-1.65) respectively for all-cause mortality, compared with 60-79 bpm. Ventricular rates ≥100 bpm among patients presenting with AF on ECG in treatment with rate control drugs were associated with greater risk of both new-onset HF and all-cause mortality.

FLOATING DRUG DELIVERY SYSTEM: A REVIEW

Recent technological and scientific research has been devoted to the development of rate-controlled drug delivery system to overcome physiological adversities such as unpredictable gastric emptying times and gastric residence time. FDDS are of particular interest of drugs that are locally active and have narrow absorption window in stomach. FDDS offers numerous advantages, specially the drugs having narrow absorption window in GIT, primary absorption in the stomach, Prolonged gastric retention improves bioavailability, reduces drug waste, and improves solubility for drugs that are least soluble in a high pH environment. This review summarizes the design of the FDDS systems, factors that affect floating system, advantages, limitations, evaluation parameters and applications.

ECG based assessment of circadian variation in AV-nodal conduction during AF-Influence of rate control drugs.

The heart rate during atrial fibrillation (AF) is highly dependent on the conduction properties of the atrioventricular (AV) node. These properties can be affected using β-blockers or calcium channel blockers, mainly chosen empirically. Characterization of individual AV-nodal conduction could assist in personalized treatment selection during AF. Individual AV nodal refractory periods and conduction delays were characterized based on 24-hour ambulatory ECGs from 60 patients with permanent AF. This was done by estimating model parameters from a previously created mathematical network model of the AV node using a problem-specific genetic algorithm. Based on the estimated model parameters, the circadian variation and its drug-dependent difference between treatment with two β-blockers and two calcium channel blockers were quantified on a population level by means of cosinor analysis using a linear mixed-effect approach. The mixed-effects analysis indicated increased refractoriness relative to baseline for all drugs. An additional decrease in circadian variation for parameters representing conduction delay was observed for the β-blockers. This indicates that the two drug types have quantifiable differences in their effects on AV-nodal conduction properties. These differences could be important in treatment outcome, and thus quantifying them could assist in treatment selection.

Acute rate control in atrial fibrillation: an urgent need for the clinician.

Rate and rhythm control are still considered equivalent strategies for symptom control using the Atrial Fibrillation Better Care algorithm recommended by the recent atrial fibrillation guideline. In acute situations or critically ill patients, a personalized approach should be used for rapid rhythm or rate control. Even though electrical cardioversion is generally indicated in haemodynamically unstable patients or for rapid effective rhythm control in critically ill patients, this is not always possible due to the high percentage of failure or relapses in such patients. Rate control remains the background therapy for all these patients, and often rapid rate control is mandatory. Short and rapid-onset-acting beta-blockers are the most suitable drugs for acute rate control. Esmolol was the classical example; however, landiolol a newer very selective beta-blocker, recently included in the European atrial fibrillation guideline, has a more favourable pharmacokinetic and pharmacodynamic profile with less haemodynamic interference and is better appropriate for critically ill patients.

Epidemiology, management, and outcomes of atrial fibrillation among 30 million citizens in Shanghai, China from 2015 to 2020: A medical insurance database study

SummaryBackgroundAtrial fibrillation(AF) has become a significant public health concern in China, with population aging and urbanization.MethodsData screening was performed for 30,244,930 subjects with medical insurance in the Shanghai Municipal Health Commission database between 2015 and 2020. Patients diagnosed with AF were identified and further assessed for treatment information and clinical outcomes, as well as sex differences and impact of COVID-19 pandemic on AF managment.FindingsAF prevalence was 0.88% in Shanghai, which increased with age and reached 6.70% at subjects 80 years and over. AF was more prevalent in women compared with men (0.89% vs. 0.88%, p<0.0001), which could be attributed to higher AF burden in women over 80 years. Driven by increased prescription of non-vitamin K antagonist oral anticoagulants, anticoagulant use increased from 19.46% in 2015 to 56.57% in 2020. The number of left atrial appendage closure increased from 0.16% in 2015 to 1.23% in 2020. Rhythm control strategy was increasingly adopted, as the use of antiarrhythmic drugs doubled and ablation increased by 21% in 2020 compared to 2015. Compared with men, women were less prone to receive rhythm control treatments, including antiarrhythmics, ablation and cardioversion, but more likely to adopt rate control drugs. During the 5.5 years follow-up, the incidences of stroke, transient ischemic attack, systemic embolism, bleeding, myocardial infarction, and in-hospital death were 6.09%, 5.74%, 1.44%, 5.11%, 8.41%, and 12.84% in patients with index diagnosis of AF in 2015, respectively.InterpretationThe burdens of AF and AF-related outcomes in Shanghai are high. Management of AF is markedly improved in recent years, and was not or only slightly impeded by the COVID-19 pandemic. There are sex differences in the prevalence, management, and outcomes of AF.FundingShanghai Hospital Development Center, National Natural Science Foundation of China and Shanghai Municipal Science and Technology Commission.

Pharmacological Management of Atrial Fibrillation: A Century of Expert Opinions in Cecil Textbook of Medicine.

Advances in drug therapy for atrial fibrillation (AF) have had a significant impact on the quality of life of a substantial majority of affected persons, which has contributed to a remarkable decrease in the frequency and severity of thromboembolic complications, hospitalizations, and mortality. What are the milestones of the changes in the expert approach to the pharmacological management of AF in the past century? To determine the changes in the experts' approach to the management of AF, as presented in a widely used textbook in the United States. The chapters presenting the management of AF in the 26 editions of Cecil Textbook of Medicine published from 1927 through 2020. AF was consistently described in Cecil Textbook of Medicine as the most common sustained arrhythmia in adults. The authors emphasized its thromboembolic complications and potential for hemodynamic deterioration. Rate control with digitalis and rhythm control with quinidine were the standard in 1927. The pharmacological advances have focused on atrioventricular nodal blocking for rate control, conversion to and maintenance of sinus rhythm, and preventive anticoagulation. The first new class of drugs for rate control was beta-adrenergic receptor blockers, starting with propranolol which was introduced in 1979, followed by the calcium channel blocker verapamil in 1988. Rhythm control with amiodarone, a potassium channel blocker, has been recommended since 2004, and the sodium channel blockers propafenone and flecainide became part of standard therapy in 2008. Anticoagulation with warfarin was recommended starting in 2000, followed by the introduction of direct thrombin inhibitor in 2012 and factor Xa inhibitors in 2016. The pharmacological management of AF was unchanged for more than 50 years (1927-1979), a period during which the devastating effects of thromboembolic complications were not addressed. The major therapeutic advance is represented by preventive anticoagulation with the newer, safer, and more user-friendly direct thrombin and factor Xa inhibitors.

Abstract 10820: Atrial Fibrillation Catheter Ablation Reduces the Risk of Dementia: A Systematic Review and Meta-Analysis

Introduction: Although atrial fibrillation (AF) has a risk of cognitive dysfunction, it is not clear whether AF catheter ablation impacts cognitive function. Catheter ablation for AF prolongs the duration of sinus rhythm, thereby improving the quality of life and theoretically reducing the risk of dementia. Objective: We investigated the association of catheter ablation for AF with the occurrence of any dementia. Methods: A systematic search using electronic databases was performed from inception until January 15, 2021. Mantel-Haenszel risk ratio (RR) random-effects model (DerSimonian and Laird method) was used to summarize data. The primary outcome was occurrence of dementia during the follow-up period. Statistical analysis was performed using a meta-package for R version 4.0 and Rstudio version 1.2. Results: A total of 3 eligible studies (retrospective and prospective) consisting of 34,360 patients [Catheter ablation = 10,862 and medical therapy (antiarrhythmic drugs or rate-control drugs) = 23,498] were included in the meta-analysis. Patients in the ablation group were younger compared to medical therapy (59.6 ± 10.4 vs 60.3 ± 10.6 years; p&lt;0.001). Hypertension (55% vs 54.4%, p = 0.31), heart failure (23.7% vs 22.1%, p = 0.001), diabetes (14% vs 15.2%, p = 0.004), cerebrovascular accident (11% vs 10%, p = 0.005) and myocardial infarction (7.5% vs 6.5%, p&lt;0.001) were most common comorbidities, respectively. There was a lower incidence of dementia in AF patients treated with catheter ablation compared to medical therapy (2% vs 3.5%, RR 0.39, 95% CI 0.22-0.70, p&lt;0.01) during a mean follow-up period of 5.44 years. Conclusion: AF ablation patients have a significantly lower risk of dementia in comparison to AF patients without ablation.